WASHINGTON, May 30, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VANDA) (NASDAQ: VNDA) today announced that data from the Phase III studies of tasimelteon in Non-24-Hour Disorder (Non-24) will be presented at SLEEP 2013, the 27th Annual Meeting of the Associated Professional Sleep Societies, LLC being held from June 1, 2013 through June 5, 2013 in Baltimore and the Endocrine Society's 95th Annual Meeting (ENDO) being held June 15, 2013 through June 18, 2013 in San Francisco. Non-24 is a serious and rare circadian rhythm disorder that affects a majority of totally blind individuals who lack light perception and cannot entrain (synchronize) their master body clock to the 24-hour day.
Tasimelteon data at SLEEP 2013 will be presented as a late breaking abstract and the data at ENDO 2013 will be presented in a poster and oral presentation. The data presentation schedule is as follows:
-- SLEEP 2013 Baltimore
Late Breaking Abstract #005 June 5, 2013 at 12:15 PM-1:30 PM
-- ENDO 2013 San Francisco
SUN-134 June 16, 2013 at 1:45 PM – 3:45 PM
SUN-137 June 16, 2013 at 1:45 PM – 3:45 PM
About Non-24-Hour Disorder
Non-24 is a serious, rare, and chronic circadian rhythm disorder characterized by the inability to entrain (synchronize) the master body clock with the 24-hour day-night cycle. Non-24 affects the majority of totally blind individuals, or between 65,000 and 95,000 people in the U.S. Non-24 occurs almost entirely in individuals who lack the light sensitivity necessary to entrain the master body clock in the brain with the 24-hour day-night cycle. Most people have a master body clock that naturally runs longer than 24-hours and light is the primary environmental cue that resets it to 24-hours each day. Individuals with Non-24 have a master body clock that continually delays, resulting in prolonged periods of misalignment between their circadian rhythms and the 24-hour day-night cycle, including the timing of melatonin and cortisol secretion and the sleep-wake cycle. As a result of this misalignment, Non-24 is associated with significant impairments in social and occupational functioning, and marked subjective distress. For more information on Non-24, please visit www.Non-24.com.
Tasimelteon is a circadian regulator in development for the treatment of Non-24. Tasimelteon is a dual melatonin receptor agonist (DMRA) with selective agonist activity at the MT1 and MT2 receptors. Tasimelteon's ability to reset the master body clock in the suprachiasmatic nucleus (SCN) results in the entrainment of the body's melatonin and cortisol rhythms with the 24-hour day-night cycle. The patent claiming tasimelteon as a new chemical entity extends through December 2022, assuming a 5-year extension to be granted under the Hatch-Waxman Act. Tasimelteon has been granted orphan drug designation for the treatment of Non-24 from both the U.S. and the European Union.
About Vanda Pharmaceuticals Inc.:
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders. For more on Vanda, please visit www.vandapharma.com.
Senior Vice President and Chief Financial Officer
Vanda Pharmaceuticals Inc.
Assistant Vice President
|SOURCE Vanda Pharmaceuticals Inc.|
Copyright©2012 PR Newswire.
All rights reserved